White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis

Background and Objective: The objective of this study was to examine the effects of natalizumab on functional parameters assessed by evoked potentials (visual [VEP], somatosensory [SEP] and motor evoked potentials [MEP]) in a cohort study in relapsing–remitting multiple sclerosis patients. Methods: EP data of 44 patients examined 12 months prior to natalizumab treatment, at the timepoint of treatment initiation and 1 year later were compared. Sum scores (VEP, MEP, SEP) were evaluated and correlated with the Expanded Disability Status Scale. Results: Improvement of the VEP sum score was found in 33% of natalizumab-treated patients but only in 9% of the same patients prior to treatment ( p = 0.041). A comparable situation was found for SEP (improvement: 32% versus 5%; worsening: 11% versus 37%; p = 0.027). For MEP no significant differences were seen (improvement: 10% versus 18%; worsening: 5% versus 29%; p = 0.60). EP recordings (VEP = SEP > MEP) have the capacity to demonstrate treatment effects of natalizumab on a functional level. Conclusions: Natalizumab therapy increases the percentage of patients showing stable or even ameliorated electrophysiological parameters in the investigated functional systems.

Download Full-text

White matter lesion loads associated with dynamic functional connectivity within attention network in patients with relapsing-remitting multiple sclerosis

Journal of Clinical Neuroscience ◽

10.1016/j.jocn.2019.03.034 ◽

2019 ◽

Vol 65 ◽

pp. 59-65 ◽

Cited By ~ 1

Author(s):

Muhua Huang ◽

Fuqing Zhou ◽

Lin Wu ◽

Bo Wang ◽

Linghong Guo ◽

...

Keyword(s):

Multiple Sclerosis ◽

White Matter ◽

Functional Connectivity ◽

White Matter Lesion ◽

Dynamic Functional Connectivity ◽

Attention Network ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy

Multiple Sclerosis Journal ◽

10.1191/1352458503ms948oa ◽

2003 ◽

Vol 9 (5) ◽

pp. 451-457 ◽

Cited By ~ 52

Author(s):

Maria Trojano ◽

Maria Liguori ◽

Damiano Paolicelli ◽

Giovanni Bosco Zimatore ◽

Francesca De Robertis ◽

...

Keyword(s):

Multiple Sclerosis ◽

Adverse Events ◽

Interferon Beta ◽

Population Based ◽

First Year ◽

Independent Population ◽

Disability Status ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

This independent, population-based surveillance study monitored the efficacy and safety of interferon beta (IFNb) products in 1033 patients with relapsing -remitting multiple sclerosis (RRMS) from 15 centres in Italy. Relapses, Expanded Disability Status Scale (EDSS) scores, and adverse events were evaluated for up to 24 months. Data of patients with a baseline EDSS score 5-3.5 are reported. The proportions of relapse-free patients were similar among the groups at 12 and 24 months (P =0.10). IFNb products produced significant reductio ns from baseline in relapse rates at 12 and 24 months (P B-0.001), with no differences among treatments (P =0.2). There were no significant differences in mean EDSS change among groups at 12 or 24 months. The IFNb-1b group showed a higher incidence of adverse events during the first year of treatment (P B-0.05) than IFNb-1a groups, and more withdrawals (10%) compared with Avonex (5%) at 24 months. IFNb products are equally effective in low disability RRMS, but IFNb-1a may have a more favorable efficacy/tolerability ratio.

Download Full-text